Friday 23 October 2026
Export PCSA’s income statement to Excel — free account
Heatwurx Inc.
PCSA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 81.0% and free cash flow grew 20.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.88
0.02
+1.08%
Follow PCSA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(270.74%) | (372.96%) | (464.99%) | (464.19%) | |
| (206.49%) | (245.66%) | (302.37%) | (262.17%) | ||
ROIC |
0.00% | (21,694.32%) | (1,064.29%) | 0.00% | |
Return on Tangible Assets |
(267.23%) | (394.48%) | 36,928.27% | 4,235.17% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(5.65) | (9.36) | (5.19) | (4.77) | |
Free Cash Flow |
(10.73) | (12.26) | (13.62) | (13.14) | |
Capital Expenditures |
— | (0.87) | (1.37) | (1.16) | |
| Other line items | |||||
Cash ROIC |
(88.39%) | (110.27%) | (321.76%) | 10,855.79% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.83 | 0.84 | 0.87 | 0.89 | |
Depreciation/Fixed assets |
0.29 | 0.32 | 0.34 | 0.38 | |
Capex/Depreciation |
0.00 | (725.42) | (1,142.08) | (970.00) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(5.65) | (8.70) | (4.67) | (4.35) | |
Capex per Share |
0.00 | (0.66) | (0.52) | (0.42) | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates